Get the app
US › Healthcare

ImageneBio, Inc. (IMA)

US · Healthcare · Biotechnology

$4.04+0.25%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-10.2M
EPS
$-0.63
EPS estimate
$-0.90

EPS came in at -0.63 against a street estimate of -0.90 — a beat of 30.0%.

Key statistics

Market cap
$47.2M
Forward P/E
0.0
P/B
0.39
Book value
$12.60
EPS (TTM)
$-4.09
52-week high
$9.10
52-week low
$3.90
50-day MA
$5.06
200-day MA
$5.79

Analyst view

Analysts rate ImageneBio, Inc. a buy (3 buy, 0 hold, 1 sell out of 4) with an average price target of $18.00.

Shareholding

Insiders
16.19%
Institutions
54.59%

Largest institutional holders

FundStake
Bvf Inc9.84%
Blue Owl Capital Holdings LP8.14%
Orbimed Advisors LLC8.06%
Cable Car Capital LLC6.93%
Omega Fund Management LLC4.04%
RTW INVESTMENTS, LLC2.97%
Vanguard Capital Management, LLC2.84%
Trails Edge Capital Partners, LP2.50%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ImageneBio, Inc. — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-19.